KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Income from Non-Controlling Interests (2016 - 2025)

Historic Income from Non-Controlling Interests for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $2.9 billion.

  • Gsk's Income from Non-Controlling Interests rose 332475.32% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 billion, marking a year-over-year increase of 5233.09%. This contributed to the annual value of $480.6 million for FY2024, which is 168.81% up from last year.
  • Per Gsk's latest filing, its Income from Non-Controlling Interests stood at $2.9 billion for Q3 2025, which was up 332475.32% from $2.2 billion recorded in Q2 2025.
  • Gsk's 5-year Income from Non-Controlling Interests high stood at $4.2 billion for Q4 2023, and its period low was $23.6 million during Q3 2022.
  • For the 5-year period, Gsk's Income from Non-Controlling Interests averaged around $1.4 billion, with its median value being $1.4 billion (2024).
  • In the last 5 years, Gsk's Income from Non-Controlling Interests crashed by 9737.04% in 2021 and then skyrocketed by 814359.23% in 2023.
  • Gsk's Income from Non-Controlling Interests (Quarter) stood at $269.6 million in 2021, then skyrocketed by 100.13% to $539.5 million in 2022, then surged by 676.6% to $4.2 billion in 2023, then fell by 9.61% to $3.8 billion in 2024, then decreased by 23.64% to $2.9 billion in 2025.
  • Its Income from Non-Controlling Interests was $2.9 billion in Q3 2025, compared to $2.2 billion in Q2 2025 and $2.2 billion in Q1 2025.